Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    SPG302

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Spinogenix Shows Positive Phase 2 Results For Tazbentetol
    Spinogenix Shows Positive Phase 2 Results For Tazbentetol

    26 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-reports-early-improvements-in-phase-2-trial-of-tazbentetol-in-patients-with-schizophrenia-at-the-schizophrenia-international-research-society-sirs-2026-annual-congress-302725950.html

    PR NEWSWIRE
    26 Mar 2026
    Share Share
    Spinogenix Wraps Phase 2 Trial Enrollment For Tazbentetol
    Spinogenix Wraps Phase 2 Trial Enrollment For Tazbentetol

    11 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-completes-enrollment-in-phase-2-clinical-trial-of-tazbentetol-for-schizophrenia-treatment-302710783.html

    PR NEWSWIRE
    11 Mar 2026
    Share Share
    Spinogenix Shows Fast, Lasting Cognitive Boost In Alzheimer
    Spinogenix Shows Fast, Lasting Cognitive Boost In Alzheimer

    08 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-reports-evidence-of-rapid-sustained-cognitive-improvement-in-alzheimers-patients-from-phase-2a-trial-of-tazbentetol-formerly-spg302-302635266.html

    PR NEWSWIRE
    08 Dec 2025
    Share Share
    Spinogenix Announces WHO Approval of 'tazbentetol'
    Spinogenix Announces WHO Approval of 'tazbentetol'

    01 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-announces-world-health-organization-approval-of-tazbentetol-as-international-non-proprietary-name-for-spg302-302628935.html

    PR NEWSWIRE
    01 Dec 2025
    Share Share
    Spinogenix Unveils Phase 2A Results For SPG302, In ALS
    Spinogenix Unveils Phase 2A Results For SPG302, In ALS

    04 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-presents-topline-phase-2a-clinical-trial-results-for-spg302-a-first-in-class-als-treatment-302603975.html

    PR NEWSWIRE
    04 Nov 2025
    Share Share
    Spinogenix Reveals Spg302's Neuroprotective Effects In Glaucoma
    Spinogenix Reveals Spg302's Neuroprotective Effects In Glaucoma

    16 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-announces-publication-of-preclinical-study-demonstrating-neuroprotective-effects-of-spg302-in-a-model-of-glaucoma-302586055.html

    PR NEWSWIRE
    16 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.